Gene Garrard Olinger
Gene Garrard Olinger, Ph.D., serves as the Principle Investigator and as the Supervisory Microbiologist of several projects focused on the development of the countermeasures against highly lethal viral hemorrhagic fever viruses (VHFV) and alpha viruses. His team has been working on the development of vaccines which has been recently advanced for preclinical and phase I clinical studies. He has been an Integral Member and now a Principle Investigator of efforts to utilize immunotherapy against VHFV. His work has focused on the development of murine and humanized monoclonal antibody against Ebola Zaire virus under DOD and NIH funding. Continuing the effort to develop therapeutics against VHFV, his team began to screen small molecules to identify VHVF antivirals. These drug discovery efforts have led to an established effort to find therapeutic molecules for Alphavirus infections. He is an Adjunct Faculty Member of Boston University and serves as the Associate Director for High Containment Laboratory Training for Boston University’s National Emerging Infectious Diseases Laboratory (NEIDL). He has served as a Subject Matter Expert for multiple federal and international panels related to biodefense and serves as an NIH Reviewer for HIV SBIR research.
Biography Updated on 14 June 2011